Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging.

Abstract:

:Much recent debate has focused on the optimal classification of epithelial neuroendocrine tumors (NETs). Multiple different systems of terminology, grading, and staging have been proposed, and some systems combine elements of grade and stage into a single prognostic classification. Recently, national and international consensus groups have attempted to standardize the classification of NETs, especially for those arising in the gastrointestinal tract and pancreas. Furthermore, the recognition that common classification criteria (such as proliferative rate) span multiple different systems allows the basic data necessary to predict outcome and tailor therapy to be included in pathology reports, even though a single uniform system of terminology may remain elusive. Formal tumor-node-metastasis (TNM)-based staging systems also have been developed recently, and advances in the treatment of some NETs (pancreatic in particular) are pointing towards the need to assess therapeutic biomarkers in routine practice. This review will present the most widely used systems for classifying, grading, and staging NETs and will summarize the recommendations for the data to be included in standard pathology reports of these uncommon tumors.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Klimstra DS

doi

10.1053/j.seminoncol.2012.11.001

subject

Has Abstract

pub_date

2013-02-01 00:00:00

pages

23-36

issue

1

eissn

0093-7754

issn

1532-8708

pii

S0093-7754(12)00200-X

journal_volume

40

pub_type

杂志文章,评审
  • Taxoids: effective agents in anthracycline-resistant breast cancer.

    abstract::The results of recent clinical trials have shown that docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France), like paclitaxel (Taxol; Bristol-Myers Squibb Oncology, Princeton, NJ), has high levels of activity in patients with anthracycline-resistant breast cancer. Agents that are at least partially non-cross-resist...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Ravdin PM

    更新日期:1995-12-01 00:00:00

  • The use of ondansetron in patients receiving multiple-day cisplatin regimens.

    abstract::The control of nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy has remained difficult, even with the use of combination antiemetic regimens containing metoclopramide. Although these patients receive a lower daily dose of cisplatin, the emetogenic potential remains high. In addition, many ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Hainsworth JD

    更新日期:1992-08-01 00:00:00

  • Efficacy of endoscopic variceal ligation for bleeding esophageal varices in patients with tumor thrombus of the portal vein trunk (Vp3) associated with hepatocellular carcinoma.

    abstract::We studied the efficacy of endoscopic variceal ligation (EVL) in 16 patients with tumor thrombus of the portal vein trunk (Vp3) associated with hepatocellular carcinoma. The average (+/-SD) number of O rings used was 9.0 +/- 5.0 for the esophageal varices (n = 7) and 16.4 +/- 4.5 for the esophagogastric varices (n = 9...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Kokubu S,Matsumoto Y,Murakami M,Shibata H,Saigenji K

    更新日期:1997-04-01 00:00:00

  • Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia.

    abstract::Preclinical models in vitro and in vivo have shown that tumor hypoxia alters the malignant cell phenotype, selecting for p53 mutations, stimulating angiogenesis and metastasis, and markedly reducing the efficacy of both radiotherapy and chemotherapy. Similarly, clinical studies measuring pretreatment tumor oxygen stat...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.31531

    authors: Gandara DR,Lara PN Jr,Goldberg Z,Le QT,Mack PC,Lau DH,Gumerlock PH

    更新日期:2002-02-01 00:00:00

  • Practical considerations in the evaluation and management of adrenocortical cancer.

    abstract::Adrenocortical cancer (ACC) is a rare, challenging disease with a broad range of clinical presentations. Often presenting in an advanced stage with a large, locally invasive primary tumor or with Cushing's syndrome, it requires a multidisciplinary approach to treatment. We discuss controversies in the evaluation and m...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2010.10.011

    authors: Balasubramaniam S,Fojo T

    更新日期:2010-12-01 00:00:00

  • Screening diagnosis and staging of esophageal cancer.

    abstract::In geographic areas where there is a high risk of esophageal cancer, analysis of cells obtained from the esophagus has been used effectively to detect early lesions. This has been demonstrated on a large scale in studies from China. Using abrasive balloon cytology techniques, 75% of the cancers detected were early les...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Lightdale CJ,Winawer SJ

    更新日期:1984-06-01 00:00:00

  • The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer.

    abstract::In recent years, several new cytotoxic agents have been investigated for the management of non-small cell lung cancer (NSCLC), including the antimetabolic gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) and the new multitargeted antifolate pemetrexed (Alimta, Eli Lilly and Company), which are both among ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00284-7

    authors: Le Chevalier T

    更新日期:2003-08-01 00:00:00

  • Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.

    abstract::There are several treatment options for patients with metastatic colorectal cancer (mCRC), including those with disease that has progressed after treatment with chemotherapy. Bevacizumab-containing regimens show good efficacy in patients with previously treated disease. Compared with infused 5-fluorouracil, leucovorin...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.08.003

    authors: Giantonio BJ

    更新日期:2006-10-01 00:00:00

  • Small cell carcinoma of the lung: cellular origin and relationship to other neoplasms.

    abstract::Many small cell carcinomas share morphological and physiological characteristics with normal and neoplastic cells of Pearse's APUD series, including pulmonary APUD cells and pulmonary carcinoid tumors. There is very likely more than one type of APUD cell in the lung, and conclusions that small cell carcinomas and carc...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Tischler AS

    更新日期:1978-09-01 00:00:00

  • Immune tolerance and transplantation.

    abstract::Successful allogeneic hematopoietic stem cell transplantation (HSCT) and solid organ transplantation require development of a degree of immune tolerance against allogeneic antigens. T lymphocytes play a critical role in allograft rejection, graft failure, and graft-versus-host disease (GVHD). T-cell tolerance occurs b...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2012.10.001

    authors: Alpdogan O,van den Brink MR

    更新日期:2012-12-01 00:00:00

  • Cardio-oncology in clinical studies and real life.

    abstract::Session V of the Colloquium was chaired by Professors Teresa López-Fernández of Spain and Grzegorz Opolski of Poland. The 3 speakers addressed cardio-oncology issues as they relate to both clinical studies and real life situations. Professor Susan Dent discussed cardio-oncology networks for patients, emphasizing the i...

    journal_title:Seminars in oncology

    pub_type:

    doi:10.1053/j.seminoncol.2019.01.004

    authors: Dent SF,Suter TM,López-Fernández T,Opolski G,Menna P,Minotti G

    更新日期:2019-12-01 00:00:00

  • Combined cytotoxic and endocrine treatment of postmenopausal patients with advanced breast cancer: preliminary results of a phase II study of the combination of prednimustine, novantrone, methotrexate, 5-fluorouracil, and tamoxifen.

    abstract::Postmenopausal patients with advanced measurable and/or evaluable breast cancer entered a phase II trial of multiple agent cytotoxic therapy combined with endocrine therapy. Cycles of PNMF (prednimustine, novantrone, methotrexate, and 5-fluorouracil) were repeated every 4 weeks as follows: P, 100 mg/m2 PO on days 1 to...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Mouridsen HT,Andersson M,Pedersen L

    更新日期:1986-03-01 00:00:00

  • MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.

    abstract::Aberrant activation of the three-layered protein kinase cascade, Raf/MEK/ERK, is often detected in human cancer, which is mainly attributed to the oncogenic alterations of RAF, or its upstream activators RAS or cell surface receptor tyrosine kinases. Deregulated activity of the Raf/MEK/ERK pathway drives uncontrolled ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.09.023

    authors: Wu PK,Park JI

    更新日期:2015-12-01 00:00:00

  • Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials.

    abstract::Based on anecdotal cases of clinically important decreases in tumor size following initial evidence of disease progression when treating patients with anti-PD-1 therapies, investigators have conducted clinical trials in patients with metastatic non-small lung cancer (mNSCLC) receiving anti-PD-1 therapy allowing for tr...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,多中心研究,评审

    doi:10.1053/j.seminoncol.2017.01.001

    authors: Kazandjian D,Keegan P,Suzman DL,Pazdur R,Blumenthal GM

    更新日期:2017-02-01 00:00:00

  • Chemotherapeutic approaches to advanced breast cancer.

    abstract::Choices of treatment for patients with estrogen receptor (ER) positive metastatic breast cancer refractory to first-line endocrine therapies include progestins, antiadrenal drugs, and androgens. These treatments should be administered sequentially to achieve maximum palliation of the disease. For ER positive patients ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Buzdar AU

    更新日期:1988-06-01 00:00:00

  • Kinetic concepts in the systemic drug therapy of breast cancer.

    abstract::Optimal management of cancer today requires a thorough and up-to-date understanding of cancer cell kinetics and biochemistry. This report reviews the history and current standards in these fields and how they affect the contemporary approach to breast cancer management. Also outlined are recommended avenues for future...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Norton L

    更新日期:1999-02-01 00:00:00

  • Lymphoma: diagnosis, staging, natural history, and treatment strategies.

    abstract::Non-Hodgkin's lymphoma (NHL) is not a single disease, but a group of closely related B- and T-cell cancers of the lymphatic system. The incidence of NHL is rising, particularly in the countries of the industrialized world. The increased incidence is poorly understood, but several risk factors have been postulated to b...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2005.01.008

    authors: Zinzani PL

    更新日期:2005-02-01 00:00:00

  • Epstein-barr virus- and Kaposi sarcoma-associated herpesvirus-related malignancies in the setting of human immunodeficiency virus infection.

    abstract::The human gammaherpesvirus family includes Epstein-Barr virus (EBV) and human herpesvirus (HHV)-8, also known as Kaposi sarcoma-associated herpesvirus (KSHV). In human immunodeficiency virus (HIV)-infected patients, both EBV and KSHV have been implicated in the development of a wide range of tumors. KSHV-associated di...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.12.026

    authors: Pinzone MR,Berretta M,Cacopardo B,Nunnari G

    更新日期:2015-04-01 00:00:00

  • New perspectives on the toxicity of etoposide.

    abstract::Etoposide has been used in the treatment of a wide variety of neoplasms, including small cell lung cancer. Kaposi's sarcoma, testicular cancer, acute leukemia, and lymphoma. Its current therapeutic use is limited by myelosuppression, particularly neutropenia. Pharmacodynamic studies of etoposide show that this toxicit...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Kobayashi K,Ratain MJ

    更新日期:1992-12-01 00:00:00

  • Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy.

    abstract::For four decades, 5-fluorouracil was the only option available for patients with metastatic colorectal cancer. It provided a response rate of 15% to 20%, with a median survival of approximately 1 year. In the past 5 years, remarkable progress has been made in colorectal cancer research with the approval of irinotecan ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.04.022

    authors: Varadhachary GR,Hoff PM

    更新日期:2005-12-01 00:00:00

  • Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.

    abstract::Adjuvant chemotherapy has a real but modest impact on the disease-free and overall survival of patients with breast cancer. Recent attempts to improve its effectiveness have focused on dose intensity and new agents. Sequential therapy maximized dose intensity while limiting overlapping toxicity. Sequential therapy usi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Hudis C,Seidman A,Raptis G,Fennelly D,Gilewski T,Baselga J,Theodoulou M,Sklarin N,Moynahan M,Surbone A,Currie V,Lebwohl D,Uhlenhopp M,Crown J,Norton L

    更新日期:1996-02-01 00:00:00

  • Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine.

    abstract::It has been a challenge to find effective chemotherapeutic treatments for malignant mesothelioma. Over the last several decades numerous single-drug and combination regimens have been examined, but no standard treatment with chemotherapy alone has emerged. Possible explanations for this lack of success are the heterog...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.30231

    authors: Baas P

    更新日期:2002-02-01 00:00:00

  • Rituximab plus chemotherapy in follicular and mantle cell lymphomas.

    abstract::Rituximab shows high single-agent activity in both previously untreated and relapsed or refractory indolent non-Hodgkin's lymphoma. In combination with chemotherapy, rituximab has achieved response rates higher than 90% with long duration of remission in phase II studies. Therefore, randomized phase III studies have b...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验,评审

    doi:10.1053/sonc.2003.50024

    authors: Hiddemann W,Dreyling M,Unterhalt M

    更新日期:2003-02-01 00:00:00

  • The human interferon-alpha species and hybrid proteins.

    abstract::Ten years of interferon (IFN) therapy have followed the approval of this agent by the US Food and Drug Administration on June 5, 1986. As the first biotherapeutic approved, IFN-alpha paved the way for the many new biotherapeutics. Regardless of this long history, however, we have just touched the surface of understand...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Pestka S

    更新日期:1997-06-01 00:00:00

  • Toxicity patterns with immunomodulating antibodies and their combinations.

    abstract::Immune checkpoint molecules cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1), but also LAG-3 and TIM-3, are involved in regulation of peripheral tolerance in order to prevent autoimmunity. Blocking of these cell surface proteins by antibodies has resulted in remarkable anti-tumor immunity; howev...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.02.011

    authors: Haanen JB,Thienen Hv,Blank CU

    更新日期:2015-06-01 00:00:00

  • The role of bone marrow transplantation in the non-Hodgkin's lymphomas.

    abstract::In a significant fraction of patients with NHL, disease develops that is resistant to conventional chemotherapy. Experience using high-dose chemotherapy, with or without TBI, and BMT is expanding. Remissions can be achieved in many patients with refractory NHL in particular those patients with tumors that are still ch...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Williams SF

    更新日期:1990-02-01 00:00:00

  • Single agents in the second-line treatment of non-small cell lung cancer.

    abstract::The options available to patients with advanced non-small cell lung cancer (NSCLC) resistant or refractory to first-line chemotherapy are very limited. The older-generation drugs (etoposide, vindesine, epirubicin, and cisplatin) that are active against previously untreated NSCLC do not achieve a response rate greater ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Belani CP

    更新日期:1998-06-01 00:00:00

  • The interface between medical oncology and supportive and palliative cancer care.

    abstract::Traditionally, medical oncology has focused on the active period of diagnosis, treatment and follow-up of cancer patients, and palliative medicine, the pre-terminal and end-of-life phases. Palliative medicine physicians have particular expertise in communication and symptom control, especially, for example, with pain ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2011.03.021

    authors: Storey DJ,Fallon MT,Smyth JF

    更新日期:2011-06-01 00:00:00

  • Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.

    abstract::Knowledge of the pharmacokinetics of a drug is essential to the optimal design of the dose and schedule of chemotherapy protocols. As an extension, an understanding of the mechanism of drug action is necessary to construct the optimal strategy for combination chemotherapy. Nucleoside antimetabolites such as fludarabin...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Plunkett W,Gandhi V,Huang P,Robertson LE,Yang LY,Gregoire V,Estey E,Keating MJ

    更新日期:1993-10-01 00:00:00

  • Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19.

    abstract::This article summarizes the likely attenuation properties of RRx-001 in COVID-19 based on its mechanism of action and the putative pathogenesis of the disease, which appears to activate inflammatory, oxidative, and immune cascades with the potential to culminate in acute respiratory distress syndrome, cytokine storm a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2020.07.002

    authors: Oronsky B,Knox S,Cabrales P,Oronsky A,Reid TR

    更新日期:2020-10-01 00:00:00